Skip to Content

Healthpeak Properties Inc PEAK

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Healthpeak Produces an In-Line Second Quarter as It Makes Progress on Senior Housing Dispositions

Kevin Brown Equity Analyst

Analyst Note

| Kevin Brown |

We are reaffirming our $33.50 fair value estimate for no-moat Healthpeak after the company reported second-quarter results that were mostly in line with our expectations. Life science produced another strong quarter, with same-store net operating income up 7.4%, slightly ahead of our 5.9% estimate. The medical office segment had its best quarter in over two years, increasing same-store NOI by 4.1%, slightly ahead of our 3.8% estimate. However, the continuing care retirement community segment saw either a 23.2% decline if government grants provided under the Cares Act in 2020 are included in the comparison or 22.7% growth if those grants are excluded. Similarly, the total company same-store NOI figure is either 1.2% if the 2020 grants are included or 7.6% if they are removed from the calculation. Healthpeak reported adjusted funds from operations of $0.40 in the second quarter, which is in line with our $0.40 estimate for the quarter, the $0.40 the company produced in the first quarter of 2021, and the $0.40 the company reported in the second quarter of 2020.

Read Full Analysis

Company Profile

Business Description

Healthpeak owns a diversified healthcare portfolio of approximately 460 in-place properties spread across senior housing, medical office, life science, hospital, and skilled nursing/post-acute care.

5050 South Syracuse Street, Suite 800
Denver, CA, 80237
T +1 949 407-0700
Sector Real Estate
Industry REIT - Healthcare Facilities
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Hard Assets
Employees 217


Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.